卡瑞利珠单抗联合安罗替尼治疗小细胞肺癌的效果及安全性

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (898 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the efficacy and safety of Carrelizumab combined with Arotinib in the treatment of small cell lung cancer (SCLC). Methods A total of 76 patients with SCLC who were admitted to Jiujiang First People′s Hospital from November 2017 to October 2019 were selected as research objects. They were divided into control group and observation group according to random number table method, with 38 cases in each group. The control group was treated with Arotinib, and the observation group was treated with Carrelizumab combined with Arotinib, with a course of treatment every 3 weeks and 6 consecutive courses of treatment. The clinical efficacy, quality of life, progression-free survival (PFS), overall survival (OS) and adverse reactions were compared between the two groups. Results There was no statistical significance in objective response rate (ORR) and disease control rate (DCR) between the two groups (P＞0.05). After 2, 4 and 6 courses of treatment, the Karnofsky score (KPS) of the observation group was higher than that of the control group, and the OS and PFS of the observation group were longer than those of the control group, the differences were statistically significant (P＜0.05). There was no statistical significance between the two groups in the total incidence of adverse reactions (P＞0.05). Conclusion Patients with SCLC treated with Carrelizumab combined with Arotinib have better effect, which is conducive to improving the quality of life, prolonging the survival time of patients and reducing toxic and side effects.

Key words： Small cell lung cancer Carrelizumab Arotinib Clinical efficacy Quality of life Survival

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yanbing
	SHI Xin
	CAI Lingyu
	ZUO Hongbo
	WANG Zhi

Cite this article:

LI Yanbing,SHI Xin,CAI Lingyu, et al. Efficacy and safety of Carrelizumab combined with Arotinib in the treatment of small cell lung cancer[J]. 中国当代医药, 2022, 29(2): 82-84转88.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2022/V29/I2/82

[1]	田浩，康晓艳，杨琳，等.外周血sPD-L1 在小细胞肺癌患者化疗期间变化及其临床意义[J].中国肿瘤临床，2019，46（9）：452-456.
[2]	高红杰，代珊珊，杨欢.安罗替尼治疗二线化疗失败的晚期非小细胞肺癌的疗效观察[J].癌症进展，2020，18（10）：1023-1026，1068.
[3]	林建光，陈平，解方为，等.安罗替尼二线治疗广泛期小细胞肺癌的临床疗效[J].肿瘤防治研究，2020，47（12）：953-957.
[4]	袁亮，侯新丽.安罗替尼在小细胞肺癌（SCLC）三线及以上治疗中的疗效及安全性[J].现代肿瘤医学，2020，28（21）：3710-3714.
[5]	冯奉仪.实体瘤新的疗效评价标准（解读1.1 版RECIST标准）[C]//中国癌症基金会、中国抗癌协会肿瘤临床化疗专业委员会、中华医学会肿瘤学分会、全国肿瘤防治研究办公室、中国医学科学院肿瘤医院.第三届中国肿瘤内科大会论文集.[出版者不详]，2009：123-125.
[6]	李群，徐鹏，熊明.中西医结合治疗对非小细胞肺癌患者疗效、毒副作用及KPS 评分的影响[J].现代中西医结合杂志，2019，28（9）：991-993.
[7]	皋文君，刘砚燕，袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0 版[J].肿瘤，2012，32（2）：142-144.
[8]	王冰睿，丰暖，石新艳，等.TTF-1 与小细胞肺癌一线化疗敏感性及预后的相关性分析[J].中国肺癌杂志，2020，23（7）：547-553.
[9]	王微，王建华，叶军辉，等.安罗替尼联合替吉奥胶囊治疗复发性或难治性小细胞肺癌的近期疗效及安全性[J].浙江医学，2019，41（23）：2536-2539.
[10]	张昊，崔秀洁，郭玉华，等.放疗联合安罗替尼对小细胞肺癌患者胱天蛋白酶3、多腺苷二磷酸核糖聚合酶表达的影响研究[J].癌症进展，2020，18（6）：603-605.
[11]	徐寿华，杜海燕.安罗替尼三线治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床与康复，2020，27（2）：214-216.
[12]	谷耀伟，李筝，宋丽杰.安罗替尼联合AP 方案治疗晚期非小细胞肺癌的临床研究[J].现代药物与临床，2020，35（9）：1869-1873.
[13]	邱亚娟，张明智.程序性死亡分子配体1 的表达与小细胞肺癌患者预后的关系[J].中华肿瘤杂志，2019，41（3）：214-217.
[14]	张明辉，王燕，李国良，等.免疫检查点PD-1/PD-L1 通路在小细胞肺癌中的作用[J].临床肿瘤学杂志，2017，22（3）：277-280.
[15]	龙方园，何芳，涂洁，等.PD－1 抑制剂（卡瑞利珠单抗）致反应性毛细血管增生症三例并文献复习[J].中国麻风皮肤病杂志，2020，36（4）：219-223.
[16]	张伟，殷海涛，周冲，等.甲磺酸阿帕替尼联合卡瑞利珠单抗治疗原发性肝癌伴肺转移一例[J].国际肿瘤学杂志，2020，47（8）：510-512.